64 active not recruiting. 64 Phase 3, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 64 | Active not recruiting 64 |
| Phase 2 | 9 | Active not recruiting 9 |
Follow Colonic Diseases: new trials by email Literature Review of Colonic Diseases trials Research Report on Colonic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test Capecitabine, Oxaliplatin, Folfirinox - Colorectal Cancer | Phase 3 | Active not recruiting | UNICANCER | 2450 | 2026-07-20 | 2026-07-22 |
| A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis Icotrokinra, Placebo - Colitis, Ulcerative | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 896 | 2025-10-01 | 2026-11-03 |
| A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab Risankizumab, Vedolizumab - Ulcerative Colitis | Phase 3 | Active not recruiting | AbbVie | 573 | 2025-06-17 | 2026-08-04 |
| Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer SMA lymph node dissection, SMV lymph node dissection - Colon Cancer | Phase 3 | Active not recruiting | Haixing Ju, MD | 896 | 2024-07-01 | 2024-11-29 |
| A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis Guselkumab Subcutaneous, Guselkumab Intravenous - Colitis, Ulcerative | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 112 | 2024-01-19 | 2026-11-03 |
| Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis. Upadacitinib - Ulcerative Colitis | Phase 3 | Active not recruiting | AbbVie | 122 | 2023-11-06 | 2026-05-14 |
| A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) IV Tulisokibart, IV Placebo, SC Tulisokibart - Ulcerative Colitis | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 1109 | 2023-10-25 | 2026-09-28 |
| Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer Encorafenib, Cetuximab, Biospecimen Collection - Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma | Phase 2 / Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 1 | 2023-08-16 | 2026-07-02 |
| A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab, HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab - Colorectal Cancer | Phase 2 / Phase 3 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 669 | 2023-08-14 | 2025-11-18 |
| Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer quality of life questionnaires, Blood sample, Regorafenib - Metastatic Colorectal Cancer | Phase 2 / Phase 3 | Active not recruiting | Centre Hospitalier Universitaire de Besancon | 446 | 2023-05-09 | 2026-11-04 |
| Ebastine Versus Mebeverine in IBS Patients Ebastine, Duspatalin - IBS - Irritable Bowel Syndrome, IBS | Phase 3 | Active not recruiting | Guy Boeckxstaens | 200 | 2023-03-30 | 2026-09-11 |
| Evaluating Novel Therapies in ctDNA Positive GI Cancers Atezolizumab, Bevacizumab - Colon Adenocarcinoma, Rectal Adenocarcinoma | Phase 3 | Active not recruiting | Georgetown University | 11 | 2023-03-29 | 2026-10-06 |
| A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer HX008(Pucotenlimab), Investigator's Choice Chemotherapy - Metastatic Colorectal Cancer | Phase 3 | Active not recruiting | Taizhou Hanzhong biomedical co. LTD | 190 | 2023-02-28 | 2026-05-14 |
| Transfer of FRozen Encapsulated Multidonor Stool Filtrate for Active Ulcerative COlitis encapsulated faecal microbiota filtrate, encapsulated faecal microbiota, Placebo - Ulcerative Colitis, Inflammatory Bowel Diseases | Phase 3 | Active not recruiting | Andreas Stallmach | 84 | 2023-01-31 | 2026-08-10 |
| ABTECT - Maintenance ABX464, Placebo - Ulcerative Colitis | Phase 3 | Active not recruiting | Abivax S.A. | 1116 | 2023-01-16 | 2026-07-07 |
| A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3 - Colitis, Ulcerative | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 418 | 2022-09-13 | 2026-11-04 |
| Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer XL092, Atezolizumab, Regorafenib - Colorectal Cancer | Phase 3 | Active not recruiting | Exelixis | 901 | 2022-09-07 | 2026-07-17 |
| Neurocognitive Effects of FMT in MDD Patients With and Without IBS Fecal Microbiota Transplantation - Major Depressive Disorder, Irritable Bowel Syndrome | Phase 2 / Phase 3 | Active not recruiting | Valerie Taylor | 133 | 2022-04-06 | 2026-03-19 |
| Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) Pembrolizumab, Oxaliplatin, Leucovorin - Colorectal Neoplasms | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 100 | 2022-04-02 | 2026-05-22 |
| A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer GRT-C901, GRT-R902, Atezolizumab - Colorectal Neoplasms | Phase 2 / Phase 3 | Active not recruiting | Seattle Project Corporation | 700 | 2022-02-12 | 2025-05-16 |
Showing 20 of 64. Sign in to see all of them.
Colorectal Neoplasms (30) · Colitis, Ulcerative (18) · Colonic Neoplasms (15) · Inflammatory Bowel Diseases (4) · Neoplasms (4) · Irritable Bowel Syndrome (3) · Rectal Neoplasms (3) · Colorectal Neoplasms, Hereditary Nonpolyposis (2) · Crohn Disease (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2)
Gastrointestinal Diseases (63) · Digestive System Diseases (62) · Intestinal Diseases (62) · Neoplasms by Site (41) · Digestive System Neoplasms (40) · Gastrointestinal Neoplasms (40) · Intestinal Neoplasms (40) · Neoplasms (38) · Rectal Diseases (31) · Colitis (18) · Gastroenteritis (18) · Inflammatory Bowel Diseases (14) · Colorectal Neoplasms (12) · Pathological Conditions, Signs and Symptoms (5)
Bevacizumab (15) · Oxaliplatin (13) · Leucovorin (11) · Capecitabine (9) · Fluorouracil (9) · Cetuximab (6) · Irinotecan (6) · Aspirin (5) · atezolizumab (5) · Fecal Microbiota Transplantation (3) · Folfox protocol (3) · Magnetic Resonance Spectroscopy (3) · Watchful Waiting (3) · dehydroftorafur (3) · encorafenib (3)
Janssen Research & Development, LLC (6) · AbbVie (4) · Pfizer (3) · Alliance for Clinical Trials in Oncology (2) · Assistance Publique - Hôpitaux de Paris (2) · Kyungpook National University Hospital (2) · Merck Sharp & Dohme LLC (2) · National Cancer Institute (NCI) (2) · Abivax S.A. (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Andreas Stallmach (1) · Anna Martling (1) · Azienda USL Reggio Emilia - IRCCS (1) · Bristol-Myers Squibb (1) · Centre Hospitalier Universitaire Dijon (1)
United States (31) · France (27) · Belgium (21) · China (21) · Germany (20) · Poland (20) · Spain (20) · Italy (19) · Netherlands (19) · United Kingdom (19) · Canada (17) · South Korea (17) · Australia (16) · Japan (16) · Czechia (15)
Yanhong Deng, M.D. (2) · Alexandra R Brandt-Kerkhof, MD (1) · Alfredo Carrato, MD, PhD (1) · Andreas Stallmach, Prof. (1) · Anna Martling, Professor (1) · Aparna Parikh, MD (1) · Arend G Aalbers, MD (1) · Bruce Sands, MD, PhD (1)
PMID 11237120, PMID 12394384, PMID 17681163, PMID 22723185, PMID 26967693, PMID 27159210, PMID 27214731, PMID 28417994, PMID 31023318, PMID 31504429, PMID 32079889, PMID 32887653, PMID 33415649, PMID 33528867, PMID 33657038, PMID 34009291, PMID 35193638, PMID 36214590, PMID 36727222, PMID 36763936, PMID 37464378, PMID 37659673, PMID 37677111, PMID 38030258, PMID 38564700, PMID 38863178, PMID 39037800, PMID 39041200, PMID 39448057, PMID 39602630, PMID 39706209, PMID 39752885, PMID 39778975, PMID 39804294, PMID 39863775, PMID 39874977, PMID 40071779, PMID 40168091, PMID 40347957, PMID 40444708, PMID 40574492, PMID 40736240, PMID 40953502, PMID 40953785, PMID 40961426, PMID 41130252, PMID 41230651, PMID 41503939, PMID 41544637, PMID 41763462
2023 (9), 2017 (4), 2018 (3), U10CA180868 (2), 2016 (1), 2025 (1), R01CA249501 (1), U10CA037429 (1), U10CA180821 (1)